期刊文献+

“冠心1号”对动脉粥样硬化大鼠MMP-9、TIMP-1的影响 被引量:3

下载PDF
导出
摘要 目的:观察具有益气养阴、活血通阳作用的中药冠心1号对动脉粥样硬化(As)大鼠血脂、AngⅡ、MMP-9、TIMP-1基因表达及蛋白表达的影响。方法:通过高脂饮食建立大鼠AS模型,72只大鼠随机分单纯高脂饮食组、高脂饮食加舒降之组、高脂饮食加冠心1号组喂养57 d。观察血脂、AngⅡ,并应用RT-PCR测定MMP-9和MMP抑制剂-l(TIMP-1)的mRNA表达,免疫组化法测定MMP-9和TIMP-l蛋白表达。结果:冠心1号组和舒降之组治疗后血脂、AngⅡ、MMP-9mRNA及蛋白表达均优于模型组(P<0.05或P<0.01)。结论:血脂、AngⅡ、MMP-9mRNA及蛋白表达可能与AS斑块不稳定性有关。
出处 《中成药》 CAS CSCD 北大核心 2009年第5期691-695,共5页 Chinese Traditional Patent Medicine
基金 浦东新区科技发展基金资助(PKJ2004-83)
  • 相关文献

参考文献5

  • 1金斗镇,杨建梅,周端.益气养阴、活血通阳法治疗冠心病心绞痛的临床研究[J].新疆中医药,2007,25(3):12-14. 被引量:9
  • 2Radomski A,Stewart M W, Jurasz P,et al. Pharmacological characteristics of solid-phase yon Willebrand factor in human platelets [J]. Br J Pharmacol,2001. 134(5) :1013.
  • 3Wassmann S, Czech T, Eickels MV, et al. Inhibition of diet-Induced atherosclerosis and endothelial dysfunction in apolipoprotein E/an. giotensin Ⅱ type 1A receptor double-knockout mice [J]. Circulation,2004,110 ( 19 ) :3062-3067.
  • 4Yoon Y W, Kwon H M, H Wang K C, et al. Up stream regulration of matrix metalloproteinase by EMMPRN ; extracellular matrix metalloproteinase inducer in advanced atheroscleroticp laque [J]. Atherosclerosis, 2005, 180 ( 1 ) : 37-44.
  • 5丁巍,魏渝娟,万德中.基质金属蛋白酶与急性冠脉综合征关系的研究进展[J].医学综述,2006,12(15):942-944. 被引量:3

二级参考文献22

  • 1Reihardt D,Sigusch HH,Hensse J,et al.Cardiac remodeling in end stage heart failure:upregulation of matrix metalloproteinase(MMP) irrespective of the underlying disease and evidence for a direct inhibitory effect of ACE inhibitors on MMP[J].J Heart,2002,88(5):525-530.
  • 2Papakonstantinou E,Roth M,Kokkas B,et al.Losartan inhibits the an giotensin Ⅱ-induced modifications on fibrinolysis and matrix deposition by primary human vascular smooth muscle cells[J].J Cardiovasc Pharmacol,2001,38(5):715-728.
  • 3Tyagi SC,Kumar S,Katwa L.Differential regulation of extracellular matrix metalloproteinase and tissue inhibitor by heparin and cholesterol in fibroblast cells[J].J Mol Cell Cardiol,1997,29(1):391-404.
  • 4Ikeda U,Shimpo M,Ohki R,et al.Fluvastatin inhibits matrix metallo proteinase-1 expression in human vascular endothelial cells[J].Hyper tension,2000,36 (3):325-329.
  • 5Mukherjee D,Nissen SE,Topol EJ Risk of cardiovascular events associated with selective COX-2 inhibitors[J].JAMA,2001,286 (8):954-959.
  • 6Morishige K,Shimokawa H,Matsumoto Y,et al.Over expression of matrixmetalloproteinase-9 promotes intravascular thrombus formation in porcine coronary arteries in vivo[J].Cardiovasc Res,2003,57 (2):572-585.
  • 7Suzuki K,Enghild JJ,Morodomi T,et al.Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin)[J].Biochemistry,1990,29(44):10261-10270.
  • 8Lee E,Vaughan DE,Parikh SH,et al.Regulation of matrix metallopro teinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells[J].Circ Res,1996,78(1):44-49.
  • 9Halpert I,Sires UI,Roby JD,et al.Matrilysin is expressed by lipid laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition,a proteoglycan substrate for the enzyme[J].Proc Natl Acad Sci USA,1996,93(18):9748-9753.
  • 10Galis ZS,Sukhova GK,Lark MW,et al.Incrensed expression of matrix metalloproteinnses and matrix degrading activity in vulnerable regions of human atherosclerotic plaques[J].J Clin Inves,1994,94 (6):2493-2503.

共引文献10

同被引文献63

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部